Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

TransThera (2617 HK) Placement: Fundraise Was Imminent, Tinengotinib Approval Near Term Trigger

TransThera Sciences (Nanjing) IPO: Uniqueness of Lead Candidate Provides Comfort for Long-Term

Equity Capital Markets

TransThera Sciences (Nanjing) / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/transthera-sciences-nanjing-inc" target="_blank" data-smartkarma-citation="entities:34404:1" rel="noopener">TransThera Sciences (Nanjing) (2617 HK)</a> announced the placement of 5.1M shares for subscription at HK$57.03 per share.</li>
<li>TransThera intends to use 57% of net proceeds for ongoing clinical trial of core product, Tinengotinib (breast cancer, hepatocellular carcinoma, castration-resistant prostate cancer), as well as manufacturing and commercialization.</li>
<li>As far as the placement is concerned, in the near to medium term the company offers promise with Tinengotinib beginning to unleash potential but lacks next formidable drug candidate.</li>
</ul>



TransThera Sciences (Nanjing) (2617 HK) announced the placement of 5.1M shares for subscription at HK$57.03 per share.
TransThera intends to use 57% of net proceeds for ongoing clinical trial of core product, Tinengotinib (breast cancer, hepatocellular carcinoma, castration-resistant prostate cancer), as well as manufacturing and commercialization.
As far as the placement is concerned, in the near to medium term the company offers promise with Tinengotinib beginning to unleash potential but lacks next formidable drug candidate.


TransThera Placement (2617 HK): Tinengotinib Alone Can’t Signal Any Major Upheaval of Fortunes